Amendment: SEC Form SC 13D/A filed by Lexaria Bioscience Corp.

8/6/24 4:11:10 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $LEXX alert in real time by email

SC 13D/A 1 13dalexx073124.txt 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Lexaria Bioscience Corp. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 52886N (CUSIP Number) Robert B. Goldberg, Esq. 5555 Glenridge Connector, Suite 675 Atlanta, Georgia 30342 (404)233-2800 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) July 31, 2024 (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a Statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [ ]. Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13D CUSIP NO. 52886N Cover Page 1 NAMES OF REPORTING PERSONS Wayne W. Boos 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [ ] 3 SEC USE ONLY 4 SOURCE OF FUNDS (See Instructions) PF 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e). [ ] 6 CITIZENSHIP OR PLACE OF ORGANIZATION U.S.A. NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 7 SOLE VOTING POWER 915,425 8 SHARED VOTING POWER 9 SOLE DISPOSITIVE POWER 915,425 10 SHARED DISPOSITIVE POWER 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 915,425 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) [ ] 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.79%1 14 TYPE OF REPORTING PERSON (See Instructions) IN SCHEDULE 13D This Amendment No. 3 relates to the Schedule 13D filed with the Securities and Exchange Commission on September 18, 2023, as amended by Amendment No. 1 filed with the Securities and Exchange Commission on February 14, 2024, and as amended by Amendment No. 2 filed with the Securities and Exchange Commission on April 25, 2024 relating to the Common Stock, Par Value $0.001 (the Common Stock) of Lexaria Bioscience Corp., a Nevada corporation (the Company). The principal executive offices of the Company are located at #100, 740 McCurdy Road, Kelowna, BC, Canada VIX 2P7. Item 5 of the Schedule is hereby amended and supplemented as follows: Item 5. Interest in Securities of the Issuer. (a) As of July 31, 2024, Wayne W. Boos beneficially owns a total of 915,425 shares of the Companys Common Stock which represent approximately 5.79% of the outstanding Common Stock, based on 15,810,205 Common Stock outstanding as of July 12, 2024, as indicated by the Company. The percentage of Mr. Boos ownership of Common Stock in the Company has varied since the filing of Amendment No. 2 to this Schedule 13D as Mr. Boos has (i) purchased additional shares of the Companys Common Stock, (ii) he has sold shares of the Companys Common Stock, and (iii) the Company has issued additional shares of Common Stock. (b) Nature of Ownership. Wayne W. Boos has the sole power to vote and direct the disposition of all of the 915,425 shares reported as beneficially owned by him. (c) Recent Transactions. In the 60 days prior to July 31, 2024, Wayne W. Boos (i) sold 242,308 shares of the Companys Common Stock for an average price per share of $3.10 and (ii) acquired 137,733 shares of the Companys Common Stock for an average price per share of $2.84 through his broker, Merrill Lynch. (d) No other person has the right to receive or the power to direct the receipt of the dividends from, or proceeds from the sale of, such securities. (e) Not applicable. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: August 6, 2024 /s/ Wayne W. Boos Wayne W. Boos 1 Based on the 15,810,205 shares of Common Stock outstanding as of July 12, 2024.

Get the next $LEXX alert in real time by email

Amendment: SEC Form SC 13D/A filed by Lexaria Bioscience Corp.

Chat with this insight

Recent Analyst Ratings for
$LEXX

$LEXX
Press Releases

Fastest customizable press release news feed in the world

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

$LEXX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Lexaria Bioscience Corp.